Acción 688166 BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas BrightGene Bio-Medical Technology Co., Ltd.

Acciones

688166

CNE100003PR1

Precio de cierre Shanghai S.E.
Otros sitios de cotización
 00:00:00 28/06/2024 		Varia. Cinco días. Varia. 1 de enero.
35 CNY +2,16 % Gráfico intradía de BrightGene Bio-Medical Technology Co., Ltd. -3,26 % 0,00 %
07/05 Las acciones chinas suben al aliviarse el mercado inmobiliario; BrightGene se dispara un 7 MT
27/04 BrightGene Bio-Medical Technology Co. Ltd. presenta los resultados del primer trimestre finalizado el 31 de marzo de 2024 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
China Shares Rise as Property Market Gets Relief; BrightGene Jumps 7%
BrightGene to Sell 500 Million Yuan Shares to Actual Controller; Shares Up 3%
BrightGene Bio-Medical Technology Co., Ltd. announced that it expects to receive CNY 499.999987 million in funding
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
BrightGene Bio-Medical Technology Co., Ltd.'s Equity Buyback announced on February 7, 2024, has closed with 363,461 shares, representing 0.09% for CNY 10.01 million.
Tranche Update on BrightGene Bio-Medical Technology Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.
Tranche Update on BrightGene Bio-Medical Technology Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
BrightGene Bio-Medical Technology Co., Ltd. announces an Equity Buyback for CNY 20 million worth of its shares.
BrightGene Bio-Medical Technology Co., Ltd. authorizes a Buyback Plan.
Oralead Pharma announced that it has received funding from HighLight Capital, Shenzhen Qianhai BangQin Investment Co., Ltd., BrightGene Bio-Medical Technology Co., Ltd., Shenyang Borui Pharmaceutical Co., Ltd.
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Chinese Regulator Issues Warning Against BrightGene Bio-Medical Chairman Over Weight Loss Claims
Kanghui Pharma Denies Speculations of Unit’s Involvement in Production of Weight-Loss Drugs
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
BrightGene Bio-Medical Technology's Unit Gets Hospital's Approval for Diabetes Drug Trial
Chinese Drug Regulator Certifies Two Drugs of BrightGene's Unit
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
BrightGene Bio-Medical to Hike Investment in API Production Project to 500 Million Yuan
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 688166
  4. Noticias BrightGene Bio-Medical Technology Co., Ltd.
  5. Otros idiomas